Brief: Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf
27/05/2025 13:09
May 27 (Reuters) - REIN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RENEW PHASE 2 TRIAL OF LTI-03 IN PATIENTS WITH IPF REIN THERAPEUTICS INC: TOPLINE INTERIM DATA FROM RENEW IS EXPECTED IN FIRST HALF OF 2026 Source text: ID:nPn15f7lca ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering